LLY

1,008.2

-0.35%↓

JNJ

229.76

+0.06%↑

ABBV

210.92

+1.82%↑

UNH

397.57

-0.56%↓

AZN

185.49

-0.26%↓

LLY

1,008.2

-0.35%↓

JNJ

229.76

+0.06%↑

ABBV

210.92

+1.82%↑

UNH

397.57

-0.56%↓

AZN

185.49

-0.26%↓

LLY

1,008.2

-0.35%↓

JNJ

229.76

+0.06%↑

ABBV

210.92

+1.82%↑

UNH

397.57

-0.56%↓

AZN

185.49

-0.26%↓

LLY

1,008.2

-0.35%↓

JNJ

229.76

+0.06%↑

ABBV

210.92

+1.82%↑

UNH

397.57

-0.56%↓

AZN

185.49

-0.26%↓

LLY

1,008.2

-0.35%↓

JNJ

229.76

+0.06%↑

ABBV

210.92

+1.82%↑

UNH

397.57

-0.56%↓

AZN

185.49

-0.26%↓

Home・Aandelen Lijst・Microbot Medical Inc

Microbot Medical Inc

Open

1.86 -15.45

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.73

Max

2.21

Belangrijke statistieken
By Trading Economics
Inkomsten	113K -3.5M
Werknemers	43
EBITDA	-561K -4.1M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+303.23% upside

Dividenden
By Dow Jones
Volgende Winsten	19 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-22M 147M
Vorige openingsprijs	17.31
Vorige sluitingsprijs	1.86

Technische score

By Trading Central

Vertrouwen

Neutral Evidence

2.52 / 2.57 Steun & Weerstand

Microbot Medical Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

13 mei 2026, 22:54 UTC

Winsten

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

13 mei 2026, 23:51 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

13 mei 2026, 23:51 UTC

Marktinformatie

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

13 mei 2026, 23:45 UTC

Marktinformatie

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

13 mei 2026, 23:45 UTC

Marktinformatie

Global Equities Roundup: Market Talk

13 mei 2026, 23:17 UTC

Winsten

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

13 mei 2026, 23:16 UTC

Winsten

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

13 mei 2026, 23:15 UTC

Winsten

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

13 mei 2026, 23:14 UTC

Winsten

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

13 mei 2026, 23:02 UTC

Marktinformatie

Winsten

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

13 mei 2026, 22:59 UTC

Marktinformatie

Winsten

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

13 mei 2026, 22:24 UTC

Winsten

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

13 mei 2026, 22:23 UTC

Winsten

Xero FY International Organic Revenue Growth 25%>XRO.AU

13 mei 2026, 22:23 UTC

Winsten

Xero FY International Revenue Growth 47%>XRO.AU

13 mei 2026, 22:22 UTC

Winsten

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

13 mei 2026, 22:19 UTC

Winsten

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

13 mei 2026, 22:19 UTC

Winsten

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

13 mei 2026, 22:18 UTC

Winsten

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

13 mei 2026, 22:16 UTC

Winsten

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

13 mei 2026, 22:15 UTC

Winsten

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

13 mei 2026, 22:15 UTC

Winsten

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

13 mei 2026, 22:13 UTC

Winsten

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

13 mei 2026, 22:12 UTC

Winsten

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

13 mei 2026, 22:11 UTC

Winsten

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

13 mei 2026, 22:11 UTC

Winsten

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

13 mei 2026, 22:10 UTC

Winsten

Xero Did Not Declare a Dividend>XRO.AU

13 mei 2026, 22:10 UTC

Winsten

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

13 mei 2026, 22:09 UTC

Winsten

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

13 mei 2026, 22:00 UTC

Winsten

Cisco to Shed Jobs for All-In AI Push -- Update

13 mei 2026, 21:11 UTC

Winsten

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

Peer Vergelijking

Prijswijziging

Microbot Medical Inc Prognose

Koersdoel

By TipRanks

303.23% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 8.75 USD 303.23%

Hoogste 12 USD

Laagste 5.5 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Microbot Medical Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

2 ratings

Buy

Hold

Sell

Gebaseerd op 2 analisten die aandelenratings hebben gegeven aan Microbot Medical Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

2.52 / 2.57Steun & Weerstand

The bullish and bearish events are balanced.

Recent bullish events outweigh bearish events.

All events are bullish.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Microbot Medical Inc

Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development; and Phase 2 collaboration agreement with Corewell Health for the development of LIBERTY endovascular robotic system. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.